BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression
- Conditions
- Human Immunodeficiency Virus (HIV) Infections
- Interventions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2010-07-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT00337467
- Locations
- 🇪🇸
Local Institution, Malaga, Spain
A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer
- Conditions
- Cancer
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT00332748
- Locations
- 🇳🇱
Local Institution, Amsterdam, Netherlands
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 89
- Registration Number
- NCT00329004
- Locations
- 🇪🇸
Local Institution, Barcelona, Spain
🇺🇸Indiana University Med Center, Indianapolis, Indiana, United States
🇺🇸The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 69
- Registration Number
- NCT00326716
- Locations
- 🇺🇸
Triple O Medical Services, P.A., West Palm Beach, Florida, United States
🇺🇸Women's Hospital Of Texas, Houston, Texas, United States
🇿🇦Local Institution, Westdene, Gauteng, South Africa
A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: AR Antagonist (BMS-641988)
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 54
- Registration Number
- NCT00326586
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University Of Wisconsin Hospital And Clinics Laboratory, Madison, Wisconsin, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer
- Conditions
- Cancer
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT00326131
- Locations
- 🇺🇸
Local Institution, San Antonio, Texas, United States
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 681
- Registration Number
- NCT00324155
- Locations
- 🇺🇸
Thompson Cancer Survival Center, Knoxville, Tennessee, United States
🇺🇸Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸St Joseph Oncology Inc, Saint Joseph, Missouri, United States
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 75
- Registration Number
- NCT00323882
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
- Conditions
- Myeloid Leukemia, Chronic, Chronic-Phase
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00324077
- Locations
- 🇺🇸
Local Institution, New York, New York, United States
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 52
- Registration Number
- NCT00320190
- Locations
- 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom